Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CRIS100

Phase 1Small molecule

CCristália Produtos Químicos Farmacêuticos Ltda.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thoracic Spinal Cord InjuryRecruiting

Thoracic Spinal Cord InjuryPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Thoracic Spinal Cord Injury

NCT05739734

Clinical

Trials by Indication[1]

Thoracic Spinal Cord Injury1 trial

Phase 1 Clinical Trial to Evaluate the Safety of CRT100 for the Treatment of Acute Spinal Cord Injury.

Recruiting·CCristália Produtos Químicos Farmacêuticos Ltda.·Phase 1·NCT05739734·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CRIS100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CRIS100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CRIS100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cristália Produtos Químicos Farmacêuticos Ltda. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCristália Produtos Químicos Farmacêuticos Ltda.

Related News